These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33197050)

  • 41. Neuropeptide Y reduces expression of social fear via simultaneous activation of Y1 and Y2 receptors.
    Kornhuber J; Zoicas I
    J Psychopharmacol; 2019 Dec; 33(12):1533-1539. PubMed ID: 31328614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased neuropeptide Y concentrations in specific hypothalamic regions of streptozocin-induced diabetic rats.
    Williams G; Gill JS; Lee YC; Cardoso HM; Okpere BE; Bloom SR
    Diabetes; 1989 Mar; 38(3):321-7. PubMed ID: 2563712
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus.
    Broberger C; Landry M; Wong H; Walsh JN; Hökfelt T
    Neuroendocrinology; 1997 Dec; 66(6):393-408. PubMed ID: 9430445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypothalamic control of bone formation: distinct actions of leptin and y2 receptor pathways.
    Baldock PA; Sainsbury A; Allison S; Lin EJ; Couzens M; Boey D; Enriquez R; During M; Herzog H; Gardiner EM
    J Bone Miner Res; 2005 Oct; 20(10):1851-7. PubMed ID: 16160743
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y receptors.
    Morris MJ; Gannan E; Stroud LM; Beck-Sickinger AG; O'Brien TJ
    Eur J Neurosci; 2007 Feb; 25(4):1136-43. PubMed ID: 17331209
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuropeptide Y induces gonadotropin-releasing hormone gene expression directly and through conditioned medium from mHypoE-38 NPY neurons.
    Dhillon SS; Gingerich S; Belsham DD
    Regul Pept; 2009 Aug; 156(1-3):96-103. PubMed ID: 19371763
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity.
    Lin EJ; Sainsbury A; Lee NJ; Boey D; Couzens M; Enriquez R; Slack K; Bland R; During MJ; Herzog H
    Endocrinology; 2006 Nov; 147(11):5094-101. PubMed ID: 16873543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis.
    Decressac M; Wright B; David B; Tyers P; Jaber M; Barker RA; Gaillard A
    Hippocampus; 2011 Mar; 21(3):233-8. PubMed ID: 20095007
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuropeptide Y inhibits hypocretin/orexin neurons by multiple presynaptic and postsynaptic mechanisms: tonic depression of the hypothalamic arousal system.
    Fu LY; Acuna-Goycolea C; van den Pol AN
    J Neurosci; 2004 Oct; 24(40):8741-51. PubMed ID: 15470140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antihyperalgesic effects of intrathecal neuropeptide Y during inflammation are mediated by Y1 receptors.
    Taiwo OB; Taylor BK
    Pain; 2002 Apr; 96(3):353-363. PubMed ID: 11973010
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced neuropeptide Y immunoreactivity and vasoconstriction in mesenteric small arteries from the early non-obese diabetic mouse.
    Gradin KA; Zhu H; Jeansson M; Simonsen U
    Eur J Pharmacol; 2006 Jun; 539(3):184-91. PubMed ID: 16707122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Central neuropeptide Y modulates binge-like ethanol drinking in C57BL/6J mice via Y1 and Y2 receptors.
    Sparrow AM; Lowery-Gionta EG; Pleil KE; Li C; Sprow GM; Cox BR; Rinker JA; Jijon AM; Peňa J; Navarro M; Kash TL; Thiele TE
    Neuropsychopharmacology; 2012 May; 37(6):1409-21. PubMed ID: 22218088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel analogues of neuropeptide Y with a preference for the Y1-receptor.
    Söll RM; Dinger MC; Lundell I; Larhammer D; Beck-Sickinger AG
    Eur J Biochem; 2001 May; 268(10):2828-37. PubMed ID: 11358498
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evidence that hypothalamic neuropeptide Y gene expression and NPY levels in the paraventricular nucleus increase before the onset of hyperphagia in experimental diabetes.
    Sahu A; Sninsky CA; Kalra SP
    Brain Res; 1997 May; 755(2):339-42. PubMed ID: 9175903
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NPY Y2 receptors in the central amygdala reduce cued but not contextual fear.
    Verma D; Wood J; Lach G; Mietzsch M; Weger S; Heilbronn R; Herzog H; Bonaventure P; Sperk G; Tasan RO
    Neuropharmacology; 2015 Dec; 99():665-74. PubMed ID: 26314208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Insulin deficiency is a specific stimulus to hypothalamic neuropeptide Y: a comparison of the effects of insulin replacement and food restriction in streptozocin-diabetic rats.
    McKibbin PE; McCarthy HD; Shaw P; Williams G
    Peptides; 1992; 13(4):721-7. PubMed ID: 1437714
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The neuropeptide Y Y5 receptor mediates the blockade of "photic-like" NMDA-induced phase shifts in the golden hamster.
    Yannielli PC; Harrington ME
    J Neurosci; 2001 Jul; 21(14):5367-73. PubMed ID: 11438613
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor. Synthesis and pharmacological evaluation of a Y2 antagonist.
    Grouzmann E; Buclin T; Martire M; Cannizzaro C; Dörner B; Razaname A; Mutter M
    J Biol Chem; 1997 Mar; 272(12):7699-706. PubMed ID: 9065428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuropeptide Y release from the paraventricular nucleus increases in association with hyperphagia in streptozotocin-induced diabetic rats.
    Sahu A; Sninsky CA; Phelps CP; Dube MG; Kalra PS; Kalra SP
    Endocrinology; 1992 Dec; 131(6):2979-85. PubMed ID: 1446635
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo.
    Bedoui S; Miyake S; Lin Y; Miyamoto K; Oki S; Kawamura N; Beck-Sickinger A; von Hörsten S; Yamamura T
    J Immunol; 2003 Oct; 171(7):3451-8. PubMed ID: 14500640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.